

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number
WO 2005/030778 A1

(51) International Patent Classification⁷: **C07D 491/04,**
A61K 31/438, A61P 25/00

(21) International Application Number:
PCT/GB2004/004116

(22) International Filing Date:
24 September 2004 (24.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/505,731 25 September 2003 (25.09.2003) US

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DORFF, Peter** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **GORDON, John** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **HEYS, John, Richard** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **KEITH, Richard, A** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **MCCARTHY, Dennis, J** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **PHILLIPS, Eifion** [GB/US]; AstraZeneca R

& D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US). **SMITH, Mark, A** [US/US]; AstraZeneca R & D Wilmington, 1800 Concord Pike, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **LIGANDS**



(I)

(57) Abstract: A radioactive compound having the formula (I), where R¹ and Ar are as defined in the specification, pharmaceutically-acceptable salts thereof, compositions containing such compounds and uses thereof in diagnosis of conditions wherein the α_7 nicotinic receptor is involved.

WO 2005/030778 A1